Fraunhofer-Institut für Toxikologie und Experimentelle Medizin

BIO-Europe 2025

Partneringkonferenz der Biotechnologiebranche / 03. November 2025 - 05. November 2025

BIO-Europe – internationales Branchentreffen

Vom 3. bis 5. November 2025 findet das internationale Branchentreffen BIO-Europe® in Wien, Österreich, statt. Treffen Sie Expertinnen und Experten des Fraunhofer ITEM vor Ort.

Veranstaltungsdetails

Programm

Weitere Informationen zur BIO-Europe 2025 finden Sie auf der Konferenz-Website.

Veranstaltungsort

Wien, Österreich

Datum

03. November 2025 - 05. November 2025

Sprache

Englisch

Dies sind unsere Themen auf der BIO-Europe 2025

Infection Research and Immunology

We provide disease-relevant, dose-dependent, and reproducible models ranging from patented in-vitro to complex ex-vivo and in-vivo solutions. As such, we are happy to test the efficacy of your lead compound:

Fully immune-competent, all-human ex-vivo models for respiratory viruses, i.e. rhinovirus, RSV, influenza, parainfluenza and SARS-CoV-2
In-vivo models in mouse and cotton rat
Bacterial infection and biofilm models, e.g. Pseudomonas aeruginosa

This expertise is complemented by close in-house interactions with our inhalation experts, enabling efficient nebulization of compounds.

Our expertise

Inhalation Toxicology

We are committed to provide customized solutions for aerosolization and testing of drug candidates including small molecules, recombinant proteins, cell and gene therapies or bacteriophages.

We are happy to support you as a reliable partner with our key expertise in:

Inhaled administration and (GLP-certified) toxicity assessment
Toxicokinetics of inhaled particles
Formulation analytics

With our inhouse-knowledge of histopathology, hematology and clinical chemistry, as well as our portfolio in safety pharmacology testing, we provide full preclinical service for translation to clinical phase trials.

Toxicology Testing

Translational Fibrosis Research

Advance the preclinical efficacy of antifibrotic therapeutics on human lung tissue for early human proof-of-concept.

Fibrosis Research

Applying stem cell technologies and differentiated cell types for safety and efficacy testing

Human immune cells derived from iPSCs

human-based screening systems for drug discovery and safety testing
functional immune cell models (e.g., macrophages) for integration into organoids and microphysiological systems (MPS), such as organ-on-a-chip platforms
automated, scalable platforms for reproducible results